[1]钟 汉,黄海华,詹先峰.托拉塞米与呋塞米对肝硬化腹水患者利尿引起的低钾血症风险对比研究[J].医学信息,2024,37(22):22-25.[doi:10.3969/j.issn.1006-1959.2024.22.005]
 ZHONG Han,HUANG Haihua,ZHAN Xianfeng.A Comparative Study of Torasemide and Furosemide on the Risk of Hypokalemia Caused by Diuresis in Patients with Cirrhotic Ascites[J].Journal of Medical Information,2024,37(22):22-25.[doi:10.3969/j.issn.1006-1959.2024.22.005]
点击复制

托拉塞米与呋塞米对肝硬化腹水患者利尿引起的低钾血症风险对比研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年22期
页码:
22-25
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
A Comparative Study of Torasemide and Furosemide on the Risk of Hypokalemia Caused by Diuresis in Patients with Cirrhotic Ascites
文章编号:
1006-1959(2024)22-0022-04
作者:
钟 汉黄海华詹先峰
瑞金市人民医院消化内科,江西 瑞金 342500
Author(s):
ZHONG HanHUANG HaihuaZHAN Xianfeng
Department of Gastroenterology,Ruijin People’s Hospital,Ruijin 342500,Jiangxi,China
关键词:
托拉塞米呋塞米肝硬化腹水利尿低钾血症
Keywords:
TorasemideFurosemideCirrhotic asciesDiuresisHypokalemia
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2024.22.005
摘要:
目的 比较托拉塞米与呋塞米对肝硬化腹水患者利尿引起的低钾血症风险。方法 选取2021年10月-2023年9月瑞金市人民医院收治的66例肝硬化腹水患者为研究对象,按照随机数字表法分为呋塞米治疗组和托拉塞米治疗组,各33例。呋塞米治疗组用呋塞米治疗,托拉塞米治疗组用托拉塞米治疗。比较两组利尿效果(体重、尿量)、血清电解质情况(血钾、血钠)及不良反应(肝肿大、感染、腹膜炎、消化道出血、肝性脑病)发生率。结果 托拉塞米治疗组利尿效果优于呋塞米治疗组(P<0.05);治疗3 d后,托拉塞米治疗组血钾、血钠水平均高于呋塞米治疗组(P<0.05);托拉塞米治疗组不良反应发生率低于呋塞米治疗组(P<0.05)。结论 托拉塞米对肝硬化腹水患者血钾、血钠等改善作用明显,能促进尿液排出,治疗效果和安全性更高,值得应用。
Abstract:
Objective To compare the risk of diuretic-induced hypokalemia between torasemide and furosemide in patients with cirrhotic ascites.Methods A total of 66 patients with cirrhotic ascites admitted to Ruijin People’s Hospital from October 2021 to September 2023 were selected as the research objects. According to the random number table method, they were divided into furosemide treatment group and torasemide treatment group, with 33 patients in each group. The furosemide treatment group was treated with furosemide, and the torasemide treatment group was treated with torasemide. The diuretic effect (body weight, urine volume), serum electrolyte (serum potassium, serum sodium) and the incidence of adverse reactions (hepatomegaly, infection, peritonitis, gastrointestinal bleeding, hepatic encephalopathy) were compared between the two groups.Results The diuretic effect of torasemide treatment group was better than that of furosemide treatment group (P<0.05). After 3 days of treatment, the levels of serum potassium and sodium in the torasemide treatment group were higher than those in the furosemide treatment group (P<0.05). The incidence of adverse reactions in the torasemide treatment group was lower than that in the furosemide treatment group (P<0.05).Conclusion Torasemide can significantly improve serum potassium and serum sodium in patients with cirrhotic ascites, promote urine excretion, and has higher therapeutic effect and safety. It is worthy of application.

参考文献/References:

[1]高林,王美蓉,陈付成.口服托拉塞米与呋塞米在心力衰竭维持治疗中疗效的比较[J].药学研究,2023,42(9):730-733.[2]王霖佳,吴建博,张云轩,等.注射用托拉塞米致老年住院患者低钾血症危险因素分析[J].中国临床医生杂志,2023,51(3):284-286.[3]宁国庆,刘厂辉,杨军,等.托拉塞米对扩张性心肌病合并心力衰竭患者心功能及生活质量的影响观察[J].中国药师,2019,22(5):867-870.[4]杨颖,杨柳,何肇晴.甘遂入药对比呋塞米对带瘤癌性腹水大鼠AQP-1表达及心肌损伤影响研究[J].四川中医,2019,37(5):48-51.[5]梁光萍,高玲,陈晓兰,等.马兰草凝胶贴剂对肝硬化腹水大鼠及其活化肝星状细胞凋亡的影响研究[J].环球中医药,2023,16(7):1309-1316.[6]何瑾瑜,曹雪艳,叶苗青,等.五苓散联合桃红四物汤治疗瘀血阻络型肝硬化腹水的临床研究[J].中西医结合肝病杂志,2022,32(9):803-806.[7]林军,朱小区,苏林红.猪苓汤加减联合西药治疗乙型病毒性肝炎肝硬化腹水临床研究[J].新中医,2022,54(4):1-4.[8]黄永恒,邹凤娇,谭惠璇,等.温通抗癌方外敷治疗晚期胃癌恶性腹水的临床研究[J].广州中医药大学学报,2022,39(6):1254-1261.[9]王会敏,韩际奥,徐于平,等.利福昔明治疗乙型肝炎肝硬化腹水疗效观察[J].新乡医学院学报,2021,38(9):842-845.[10]钱静燕,刘琴,吴忠芳,等.何氏肚脐贴对肝硬化腹水患者腹水及血清相关炎性细胞因子水平的影响[J].现代中西医结合杂志,2020,29(33):3700-3703.[11]徐力力,苏良,王晨,等.托伐普坦治疗伴低钠血症肝硬化腹水患者的疗效[J].中国肝脏病杂志(电子版),2018,10(2):87-90.[12]刘沫然,陈怀宇,王瑞胜.失代偿期肝硬化并发肝腹水经特利加压素联合托拉塞米治疗的疗效观察[J].医药论坛杂志,2021,42(9):118-122.[13]侯浩彬,高乾峰.五苓散加减联合托拉塞米治疗肝硬化难治性腹水临床疗效及安全性分析[J].河北中医,2019,41(3):410-413,417.[14]施淑华,何道兴,林赛金.托伐普坦片治疗肝硬化腹水、低钠血症的效果及安全性[J].传染病信息,2021,34(3):246-249.[15]侯环荣,康谊.肝硬化合并自发性细菌性腹膜炎患者外周血和腹水CD100水平和免疫调节作用[J].中华肝脏病杂志,2023,31(2):138-146.[16]周翔天,夏粤华,李旭,等.三种不同技术治疗老年顽固性肝硬化腹水效果对比[J].中国老年学杂志,2022,42(7):1626-1629.[17]王征,侯维,张维,等.利福昔明改善肝硬化难治型腹水患者临床症状及短期生存情况[J].中华肝脏病杂志,2022,30(11):1170-1174.[18]陈攀丽,张炳勇,付雪琴,等.肝硬化合并自发性细菌性腹膜炎患者外周血和腹水中固有淋巴样细胞亚群的变化[J].中华医学杂志,2022,102(2):141-146.[19]江萍,豆仁成,崔子瑾,等.白蛋白-胆红素评分联合腹水中性粒细胞计数及降钙素原对肝硬化腹水患者发生自发性细菌性腹膜炎的预测价值[J].临床肝胆病杂志,2021,37(9):2097-2101.[20]邢枫,李爽,张建军,等.特利加压素对顽固性肝硬化腹水的治疗作用与效应特点观察[J].中华肝脏病杂志,2019,27(12):982-988.

相似文献/References:

[1]栾学冰.托拉塞米联合多巴胺持续静脉泵入治疗利尿剂抵抗的老年心力衰竭的疗效[J].医学信息,2020,33(10):159.[doi:10.3969/j.issn.1006-1959.2020.10.048]
 LUAN Xue-bing.Therapeutic Effect of Torasemide Combined with Dopamine Continuous Intravenous Pumping in the Treatment of Diuretic Resistant Elderly Heart Failure[J].Journal of Medical Information,2020,33(22):159.[doi:10.3969/j.issn.1006-1959.2020.10.048]
[2]廖 翔.人血白蛋白联合呋塞米对肝硬化难治性腹水患者肝肾功能的影响[J].医学信息,2021,34(21):106.[doi:10.3969/j.issn.1006-1959.2021.21.028]
 LIAO Xiang.Effect of Human Blood Albumin Combined with Furosemide on Liver and Kidney Function in Patients with Cirrhosis-refractory Ascites[J].Journal of Medical Information,2021,34(22):106.[doi:10.3969/j.issn.1006-1959.2021.21.028]

更新日期/Last Update: 1900-01-01